Abstract
Duchenne muscular dystrophy (DMD) is the most common childhood neuromuscular disorder. It is caused by mutations in the DMD gene that disrupt the open reading frame (ORF) preventing the production of functional dystrophin protein. The loss of dystrophin ultimately leads to the degeneration of muscle fibres, progressive weakness and premature death. Antisense oligonucleotides (AOs) targeted to splicing elements within DMD pre-mRNA can induce the skipping of targeted exons, restoring the ORF and the consequent production of a shorter but functional dystrophin protein. This approach may lead to an effective disease modifying treatment for DMD and progress towards clinical application has been rapid. Less than a decade has passed between the first studies published in 1998 describing the use of AOs to modify the DMD gene in mice and the results of the first intramuscular proof of concept clinical trials. Whilst phase II and III trials are now underway, the heterogeneity of DMD mutations, efficient systemic delivery and targeting of AOs to cardiac muscle remain significant challenges. Here we review the current status of AO-mediated therapy for DMD, discussing the preclinical, clinical and regulatory hurdles and their possible solutions to expedite the translation of AO-mediated exon skipping therapy to clinic.
Keywords: Antisense oligonucleotides, clinical trials, duchenne muscular dystrophy, becker muscular dystrophy, dystrophin, exon skipping, RNA therapy, BMD, PMO, DMD
Current Gene Therapy
Title:Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Volume: 12 Issue: 3
Author(s): Virginia Arechavala-Gomeza, Karen Anthony, Jennifer Morgan and Francesco Muntoni
Affiliation:
Keywords: Antisense oligonucleotides, clinical trials, duchenne muscular dystrophy, becker muscular dystrophy, dystrophin, exon skipping, RNA therapy, BMD, PMO, DMD
Abstract: Duchenne muscular dystrophy (DMD) is the most common childhood neuromuscular disorder. It is caused by mutations in the DMD gene that disrupt the open reading frame (ORF) preventing the production of functional dystrophin protein. The loss of dystrophin ultimately leads to the degeneration of muscle fibres, progressive weakness and premature death. Antisense oligonucleotides (AOs) targeted to splicing elements within DMD pre-mRNA can induce the skipping of targeted exons, restoring the ORF and the consequent production of a shorter but functional dystrophin protein. This approach may lead to an effective disease modifying treatment for DMD and progress towards clinical application has been rapid. Less than a decade has passed between the first studies published in 1998 describing the use of AOs to modify the DMD gene in mice and the results of the first intramuscular proof of concept clinical trials. Whilst phase II and III trials are now underway, the heterogeneity of DMD mutations, efficient systemic delivery and targeting of AOs to cardiac muscle remain significant challenges. Here we review the current status of AO-mediated therapy for DMD, discussing the preclinical, clinical and regulatory hurdles and their possible solutions to expedite the translation of AO-mediated exon skipping therapy to clinic.
Export Options
About this article
Cite this article as:
Arechavala-Gomeza Virginia, Anthony Karen, Morgan Jennifer and Muntoni Francesco, Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges, Current Gene Therapy 2012; 12 (3) . https://dx.doi.org/10.2174/156652312800840621
DOI https://dx.doi.org/10.2174/156652312800840621 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Subject Index To Volume 2
Current Cardiology Reviews Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Pharmacological Characteristics and Clinical Applications of K201
Current Clinical Pharmacology Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Clinical Application of Ghrelin
Current Pharmaceutical Design Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis
Current Alzheimer Research Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Glucose Intolerance and Diabetes Mellitus in Endocrine Disorders – Two Case Reports and a Review
Current Diabetes Reviews